- Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%
- Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted share
- Non-GAAP earnings* of $0.15 per diluted share increased 200%
- Cash from operations of $30.1 million increased 192%
- Company reaffirms revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025
DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025.
“Momentum continued to build across our portfolio as our team delivered an exceptional quarter reflecting above-market organic* revenue growth, increased profitability, and significant cash flow acceleration,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “Looking ahead, we remain committed to delivering on our 2025 objectives, investing in our strategic growth initiatives, and enhancing value for our customers, patients and shareholders.”
Third Quarter 2025 Financial Results
For the third quarter, worldwide revenue of $138.7 million advanced 8.2% on an organic basis as a result of above-market growth across all three areas of the Company’s broad portfolio. Reported revenue declined 0.2% from $139.0 million in the prior-year period due to the impact of the prior-year divestiture of the Advanced Rehabilitation Business.
Net income attributable to Bioventus Inc. of $3.2 million compared to a net loss attributable to Bioventus Inc. of $5.2 million in the prior-year period.
Adjusted EBITDA* of $26.6 million increased 12.9% from $23.6 million in the prior-year period, while Adjusted EBITDA* margin of 19.2% expanded 220 basis points from 17.0% last year. Higher organic* revenue growth and gross margin, as well as disciplined spending more than offset the impact of the divestiture of the Advanced Rehabilitation Business and the impact of foreign currency and tariffs.
GAAP earnings of $0.05 per diluted share of Class A common stock improved from the diluted loss of $0.08 per share in the prior-year period. Non-GAAP earnings of Class A common stock* of $0.15 per diluted share, reflect an increase of 200% from $0.05 per diluted share in the prior-year period driven by improved operating profitability and lower interest expense.
*See below under “Use of Non-GAAP Financial Measures” for more details.
